Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda

The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the third-line setting, whereas uptake of CD-19 targeted CART-Ts and CD79b targeted ADC is expected in the earlier lines. R-CHOP is being evaluated in combination with ADCs, bispecific antibodies, BTK inhibitors, and monoclonal antibodies to strengthen the response rate in the first-line treatment of DLBCL.

DelveInsight’s Diffuse Large B-cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, DLBCL emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Diffuse Large B-cell Lymphoma Market Report

• As per DelveInsight’s analysis, the DLBCL market size in the 7MM was found to be USD 3.7 billion in 2021 and it is anticipated to grow at a significant CAGR by 2032.
• As per DelveInsight estimates, total incident cases of DLBCL in the 7MM were assessed to be ~73,590 in 2021, and are expected to increase during the study period (2019–2032). Among the 7MM, the US accounts for the highest incidence cases of DLBCL, followed by EU4 and the UK, and Japan 
• Leading diffuse large B-cell lymphoma companies such as AbbVie, Genmab, Merck, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Roche, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, Gilead Sciences, AstraZeneca, and others are developing novel diffuse large B-cell lymphoma drugs that can be available in the diffuse large B-cell lymphoma market in the coming years.
• Some of the key therapies for diffuse large B-cell lymphoma treatment include  Epcoritamab, Zilovertamab vedotin, Glofitamab, Plamotamab, Enzastaurin (DB102), Mivavotinib, Maveropepimut-S, LUNSUMIO (mosunetuzumab), Obe-cel, ALLO-501A, YTB323, Zamtocabtagene autoleucel (MB-CART2019.1), Odronextamab (REGN1979), Debio 1562, ADCETRIS (Brentuximab Vedotin), Magrolimab, IMFINZI (durvalumab), CALQUENCE (acalabrutinb), and others. 
• In July 2023, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending conditional marketing authorization for epcoritamab-bysp (Tepkinly) monotherapy in adult patients with relapsed/refractory DLBCL after two or more lines of systemic therapy.
• In July 2023, the European Commission (EC) granted conditional marketing approval to Roche’s bispecific antibody (bsAb) glofitamab, marketed as Columvi, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
• In April 2023, the FDA granted approval for Polivy (polatuzumab vedotin-piiq) in conjunction with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), who possess an International Prognostic Index (IPI) score of two or higher.

Discover which therapies are expected to grab the major diffuse large B-cell lymphoma market share @ Diffuse Large B-cell Lymphoma Market Report

Diffuse Large B-cell Lymphoma Overview

Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin lymphoma (NHL) caused by aberrant B-lymphocytes. It develops from germinal center and post-germinal center B-cells. DLBCL etiology is complex and multifactorial. DLBCL can develop spontaneously or as a result of the transition of indolent diseases such as chronic lymphocytic lymphoma/small lymphocytic lymphoma, follicular lymphoma, and marginal zone lymphoma. The earliest sign of DLBCL is painless, fast swelling produced by swollen lymph nodes in the neck, underarms, or groin. The swelling may be uncomfortable for some people. Night sweats, fever, and unexpected weight loss are some symptoms. Patients may also experience weariness, appetite loss, shortness of breath, or discomfort. DLBCL is diagnosed with a biopsy of a portion or all of the lump, swollen lymph node, or aberrant region. To assess general health, laboratory procedures such as complete blood count, serum electrolyte levels, lactate dehydrogenase and uric acid levels, hepatitis B testing, and flow cytometry are utilized.

Diffuse Large B-cell Lymphoma Epidemiology Segmentation

The diffuse large B-cell lymphoma epidemiology section provides insights into the historical and current diffuse large B-cell lymphoma patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The diffuse large B-cell lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total DLBCL Incident Cases
• DLBCL Gender-specific Cases
• DLBCL Age-specific Cases
• DLBCL Type-specific Cases
• DLBCL Stage-specific Cases

Download the report to understand which factors are driving diffuse large B-cell lymphoma epidemiology trends @ Diffuse Large B-cell Lymphoma Epidemiological Insights

Diffuse Large B-cell Lymphoma Treatment Market 

Chemotherapy, radiation therapy, and immunotherapy are all treatment options for B-cell lymphoma. The treatment option chosen is determined by the symptoms, age, and rate of growth, as well as whether individuals experience various patterns of recurrence needing further lines of rescue therapy. Chemotherapy is the primary treatment for most forms of B-cell NHL. A combination of chemotherapy and the monoclonal antibody rituximab (Rituxan), with or without radiation therapy, can result in disease remission in many individuals with this type of lymphoma. If two or more treatments have failed, CAR-T cell therapies or monoclonal antibodies targeting CD79b can be investigated. Clinical trials of novel therapies may also be a viable choice for some patients.

R-CHOP [rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone] is the most commonly utilized frontline treatment. R-CHOP is typically administered every three weeks for six cycles. However, certain patients with more aggressive or large-cell lymphomas have different mutational patterns and may benefit from chemotherapy regimens such as rituximab with EPOCH [etoposide, prednisone, vincristine, cyclophosphamide, doxorubicinhydrochloride].

The introduction of CAR-T treatments such as KYMRIAH and YESCARTA for the 3L treatment of DLBCL patients has had a significant influence on the industry. Polivy, an antibody-drug conjugate, was also approved in 3L patients. Keytrudagot was approved for the PMBCL kind of DLBCL, while Selinexor from Karyopharm was approved for patients who were refractory to CAR-T cell treatments. Furthermore, Breyanzi, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed by BMS, was approved in February 2021 for the treatment of adult patients with R/R large B-cell lymphoma following two or more lines of systemic therapy.

To know more about diffuse large B-cell lymphoma treatment, visit @ Diffuse Large B-cell Lymphoma Treatment Drugs 

Key Diffuse Large B-cell Lymphoma Therapies and Companies

• Epcoritamab: AbbVie and Genmab
• Zilovertamab vedotin: Merck
• Glofitamab: Roche
• Plamotamab: Xencor and Janssen
• Enzastaurin (DB102): Denovo Biopharma
• Mivavotinib: Calithera Biosciences
• Maveropepimut-S: IMV
• LUNSUMIO (mosunetuzumab): Roche and Biogen
• Obe-cel: Autolus Therapeutics
• ALLO-501A: Allogene Therapeutics
• YTB323: Novartis
• Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine
• Odronextamab (REGN1979): Regeneron Pharmaceuticals
• Debio 1562: Debiopharm
• ADCETRIS (Brentuximab Vedotin): Seagen/Takeda
• Magrolimab: Gilead Sciences
• IMFINZI (durvalumab): AstraZeneca
• CALQUENCE (acalabrutinb): AstraZeneca

Learn more about the FDA-approved drugs for diffuse large B-cell lymphoma @ Drugs for Diffuse Large B-cell Lymphoma Treatment 

Diffuse Large B-cell Lymphoma Market Dynamics

The dynamics of the DLBCL market are anticipated to change in the coming years. Lymphoma incidence has increased in recent years, prompting pharmaceutical companies to boost their emphasis. Knowledge of the biology of DLBCL has improved in recent years, allowing for a clearer knowledge of the disease’s molecular mechanisms. In addition, in front-line settings, rituximab dominates the DLBCL market, but there is still room for other medications, with or without rituximab. Moreover, artificial intelligence (AI) technology has recently demonstrated promising results in lowering pathologist labor and boosting diagnostic accuracy, therefore enhancing the DLBCL market landscape.

However, several factors may impede the growth of the DLBCL market. All B-cell NHL subtypes continue to be treated with generic chemotherapy. Although the inclusion of rituximab improves outcomes in B-cell lymphoma patients, a large number of individuals are rituximab refractory at the time of relapse. There are no definitive biomarkers for progressive or transformational disease. The expected launch of biosimilars and generics of rituximab and lenalidomide will reduce the size of the DLBCL market. Moreover, the cost of treating DLBCL is very costly, and future therapeutic alternatives such as additional CAR-T-cell treatments, antibodies, and kinase inhibitors are also predicted to be expensive. Reimbursement agencies will try to limit the pricing and use of the expensive agent.

Scope of the Diffuse Large B-cell Lymphoma Market Report

• Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and emerging therapies
• Diffuse Large B-cell Lymphoma Market Dynamics: Attribute Analysis of Emerging Diffuse Large B-cell Lymphoma Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Diffuse Large B-cell Lymphoma Market Access and Reimbursement

Discover more about diffuse large B-cell lymphoma drugs in development @ Diffuse Large B-cell Lymphoma Clinical Trials

Table of Contents

Related Reports

Diffuse Large B-cell Lymphoma Epidemiology Forecast

Diffuse Large B-cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted diffuse large B-cell lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diffuse Large B-cell Lymphoma Pipeline

Diffuse Large B-cell Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diffuse large B-cell lymphoma companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, among others.

B-Cell Lymphoma Market

B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others.

B-cell Lymphoma Pipeline

B-cell Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key B-cell lymphoma companies, including Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., among others.

B-Cell Lymphoma Epidemiology

B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends.

Other Trending Reports

Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter